Virginia is currently home to 1851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Children's Hospital of The King's Daughters, Norfolk, Virginia
Conditions: Neuroblastoma
Register for Updates
Next Generation Rocklatan
NCT06441643
Recruiting
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Piedmont Eye Center, Lynchburg, Virginia
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
09/16/2024
Locations: Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia
Conditions: Pompe Disease (Late-onset)
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
NCT06472661
Recruiting
This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Advanced Melanoma
Register for Updates
Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions
NCT06070454
Recruiting
Primary: * To measure the rate of perioperative vulvovaginitis in a population of patients in central VA with non-malignant vulvar disease who require surgical excision * To correlate the rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown in patients undergoing SPV/WLE for vulvar disease We will use a vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida. The swab will be collected preoperatively on... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Vaginitis, Vulvar Diseases
Register for Updates
Effectiveness of Remote Foot Temperature Monitoring
NCT05728411
Recruiting
Diabetic foot ulcers are common, debilitating, and costly complications of diabetes, disproportionately impacting Black and rural Veterans. Forty percent of individuals have an ulcer recurrence within a year of ulcer healing and 65% within 5 years. Monitoring plantar foot temperatures is one of the few interventions that reduces the risk of ulcer recurrence. Despite the evidence, adoption has been poor because the original procedures, including the use of handheld thermometers, were burdensome a... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/11/2024
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Diabetic Foot
Register for Updates
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects with Endometriosis-Associated Pain
NCT05101317
Recruiting
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
09/11/2024
Locations: Tidewater Clinical Research/TPW, Norfolk, Virginia
Conditions: Endometriosis
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Loss of Y Chromosome in Aortic Stenosis
NCT06595407
Recruiting
The most common heart valve disease in humans is aortic stenosis which is a critical narrowing of the valve through which the heart has to pump blood to the rest of the body. This condition occurs in 2-3% of adults over 65 years of age and when it progresses to a severe stage leads to heart failure and need for valve replacement procedures (including surgery and catheter-based replacement). Aortic stenosis has a strong male predominance. The purpose of this study is to evaluate whether loss of Y... Read More
Gender:
MALE
Ages:
40 years and above
Trial Updated:
09/10/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Aortic Stenosis
Register for Updates
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
NCT06382168
Recruiting
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Immune Registry for Organ Transplantation From COVID Positive Donors.
NCT05595837
Recruiting
The purpose of this study is to collect data generated by standard clinical practice to determine the short term and long term clinical outcomes of recipients of solid organ transplantation from COVID-19 infected donors and compare it to recipients with organ transplant from COVID-19 negative donors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: COVID-19, Organ Transplant
Register for Updates